| The LEDGF/p75 integrase binding domain interactome contributes to the survival, clonogenicity, and tumorsphere formation of docetaxel-resistant prostate cancer cells GL Ortiz-Hernandez, ES Sanchez-Hernandez, PT Ochoa, CC Elix, ... Cells 10 (10), 2723, 2021 | 11 | 2021 |
| Glucocorticoid Receptor and β-Catenin Interact in Prostate Cancer Cells and Their Co-Inhibition Attenuates Tumorsphere Formation, Stemness, and Docetaxel Resistance SR Martinez, CC Elix, PT Ochoa, ES Sanchez-Hernandez, HR Alkashgari, ... International Journal of Molecular Sciences 24 (8), 7130, 2023 | 8 | 2023 |
| TSLP as a Potential Therapy in the Treatment of CRLF2 B Cell Acute Lymphoblastic Leukemia HR Alkashgari, C Ruiz-Jimenez, C Stoian, JS Coats, I Baez, E Chirshev, ... International journal of molecular sciences 24 (1), 474, 2022 | 4 | 2022 |
| Glucocorticoid receptor regulates and interacts with LEDGF/p75 to promote docetaxel resistance in prostate cancer cells ES Sanchez-Hernandez, PT Ochoa, T Suzuki, GL Ortiz-Hernandez, ... Cells 12 (16), 2046, 2023 | 2 | 2023 |
| The glucocorticoid receptor and β-catenin interact in prostate cancer cells and their co-inhibition attenuates stemness and docetaxel resistance SR Martinez, CC Elix, PT Ochoa, ES Sanchez-Hernandez, HR Alkashgari, ... Cancer Research 82 (12_Supplement), 399-399, 2022 | | 2022 |
| Molecular mechanisms of TSLP as a therapy for CRLF2 B-Cell acute lymphoblastic leukemia H Alkashgari, C Stoian, C Ruiz-Jimenez, J Coats, CA Casiano, S Dovat, ... Cancer Research 82 (12_Supplement), 1528-1528, 2022 | | 2022 |
| High-dose TSLP decreases in vivo tumor burden in preclinical models of CRLF2 B-ALL C Ruiz-Jimenez, J Coats, C Stoian, I Baez, H Alkashgari, A Paz-Aldana, ... Cancer Research 80 (16_Supplement), 470-470, 2020 | | 2020 |
| Developing a novel biologic for the treatment of high-risk B cell acute lymphoblastic leukemia C Ruiz-Jiménez, J Coats, X Meng, C Stoian, I Baez, H AlKashgari, ... The Journal of Immunology 204 (1_Supplement), 163.17-163.17, 2020 | | 2020 |
| Mechanism of biologic therapy for pre B-cell acute lymphoblastic leukemia with CRLF2 overexpression. WA Watson, C Stoian, JS Coats, H AlKashgari, V Vidales, I Baez, ... Journal of Clinical Oncology 37 (15_suppl), 7035-7035, 2019 | | 2019 |
| High-Dose TSLP Induces Co-Receptor Internalization and Signal Shutdown in Ph-like B-ALL with Overexpression of CRLF2 WAB Watson, H Alkashgari, C Stoian, JS Coats, I Baez, H Choi, B Becerra, ... Blood 132, 4024, 2018 | | 2018 |
| Mechanisms of novel cytokine therapy for Ph-like B-cell acute lymphoblastic leukemia with overexpression of CRLF2 C Stoian, JS Coats, H Alkashgari, V Vidales, I Baez, J Personius, H Choi, ... Cancer Research 78 (13_Supplement), 3169-3169, 2018 | | 2018 |
| Biologic for the treatment of CRLF2 B-cell acute lymphoblastic leukemia to reduce pediatric cancer health disparities C Stoian, JS Coats, V Vidales, J Personius, E Chirshev, H Alkashgari, ... CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION 27 (7), 145-146, 2018 | | 2018 |
| Abstract B71: Biologic for the treatment of CRLF2 B-cell acute lymphoblastic leukemia to reduce pediatric cancer health disparities C Stoian, JS Coats, V Vidales, J Personius, E Chirshev, H Alkashgari, ... Cancer Epidemiology, Biomarkers & Prevention 27 (7_Supplement), B71-B71, 2018 | | 2018 |
| NOVEL BIOLOGIC FOR THE TREATMENT OF PH-LIKE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH OVER EXPRESSION OF CRLF2 C Stoian, J Coats, H Alkashgari, V Vidales, I Baez, J Personius, H Choi, ... PEDIATRIC BLOOD & CANCER 65, 2018 | | 2018 |
| Biologic for the Treatment of Ph-like B-Cell Acute Lymphoblastic Leukemia with Overexpression of CRLF2 C Stoian, JS Coats, V Vidales, I Baez, J Personius, H Choi, L Liu, ... Blood 130, 2600, 2017 | | 2017 |
